JP2018512959A - 治癒向上のための二層デバイス - Google Patents
治癒向上のための二層デバイス Download PDFInfo
- Publication number
- JP2018512959A JP2018512959A JP2017554554A JP2017554554A JP2018512959A JP 2018512959 A JP2018512959 A JP 2018512959A JP 2017554554 A JP2017554554 A JP 2017554554A JP 2017554554 A JP2017554554 A JP 2017554554A JP 2018512959 A JP2018512959 A JP 2018512959A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- layer
- wound dressing
- cell
- spaced apart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035876 healing Effects 0.000 title description 27
- 238000000034 method Methods 0.000 claims abstract description 66
- 239000000463 material Substances 0.000 claims abstract description 54
- 230000033115 angiogenesis Effects 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- 239000000654 additive Substances 0.000 claims abstract description 14
- 230000000996 additive effect Effects 0.000 claims abstract description 14
- 230000010261 cell growth Effects 0.000 claims abstract description 14
- 239000000126 substance Substances 0.000 claims abstract description 12
- 230000035755 proliferation Effects 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 202
- 239000000499 gel Substances 0.000 claims description 78
- 229920001661 Chitosan Polymers 0.000 claims description 43
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 33
- -1 polyethylene Polymers 0.000 claims description 33
- 229920000642 polymer Polymers 0.000 claims description 22
- 239000004632 polycaprolactone Substances 0.000 claims description 20
- 235000010443 alginic acid Nutrition 0.000 claims description 16
- 229920000615 alginic acid Polymers 0.000 claims description 16
- 229920001577 copolymer Polymers 0.000 claims description 16
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 15
- 229940072056 alginate Drugs 0.000 claims description 15
- 239000004626 polylactic acid Substances 0.000 claims description 15
- 239000004814 polyurethane Substances 0.000 claims description 15
- 229920002635 polyurethane Polymers 0.000 claims description 15
- 210000002919 epithelial cell Anatomy 0.000 claims description 14
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 14
- 108010010803 Gelatin Proteins 0.000 claims description 13
- 229920000159 gelatin Polymers 0.000 claims description 13
- 239000008273 gelatin Substances 0.000 claims description 13
- 235000019322 gelatine Nutrition 0.000 claims description 13
- 235000011852 gelatine desserts Nutrition 0.000 claims description 13
- 210000004907 gland Anatomy 0.000 claims description 13
- 230000002062 proliferating effect Effects 0.000 claims description 13
- 229920001169 thermoplastic Polymers 0.000 claims description 13
- 229920001710 Polyorthoester Polymers 0.000 claims description 12
- 238000005094 computer simulation Methods 0.000 claims description 12
- 239000002745 poly(ortho ester) Substances 0.000 claims description 12
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 12
- 210000002985 organ of corti Anatomy 0.000 claims description 11
- 229920002988 biodegradable polymer Polymers 0.000 claims description 10
- 239000004621 biodegradable polymer Substances 0.000 claims description 10
- 210000003734 kidney Anatomy 0.000 claims description 10
- 239000004416 thermosoftening plastic Substances 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 9
- 210000003484 anatomy Anatomy 0.000 claims description 9
- 229920001400 block copolymer Polymers 0.000 claims description 9
- 210000002510 keratinocyte Anatomy 0.000 claims description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 9
- 238000010146 3D printing Methods 0.000 claims description 8
- 239000004698 Polyethylene Substances 0.000 claims description 8
- 210000002615 epidermis Anatomy 0.000 claims description 8
- 210000005036 nerve Anatomy 0.000 claims description 8
- 229920000573 polyethylene Polymers 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 7
- 230000001817 pituitary effect Effects 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 210000003403 autonomic nervous system Anatomy 0.000 claims description 6
- 210000000270 basal cell Anatomy 0.000 claims description 6
- 210000003169 central nervous system Anatomy 0.000 claims description 6
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 210000002569 neuron Anatomy 0.000 claims description 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 230000001953 sensory effect Effects 0.000 claims description 6
- 229940005605 valeric acid Drugs 0.000 claims description 6
- 229920001963 Synthetic biodegradable polymer Polymers 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 210000001508 eye Anatomy 0.000 claims description 5
- 229920005615 natural polymer Polymers 0.000 claims description 5
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 210000002449 bone cell Anatomy 0.000 claims description 4
- 201000010063 epididymitis Diseases 0.000 claims description 4
- 210000000981 epithelium Anatomy 0.000 claims description 4
- 210000001156 gastric mucosa Anatomy 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 210000000110 microvilli Anatomy 0.000 claims description 4
- 210000003097 mucus Anatomy 0.000 claims description 4
- 210000000287 oocyte Anatomy 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 210000000277 pancreatic duct Anatomy 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 210000003079 salivary gland Anatomy 0.000 claims description 4
- 210000001625 seminal vesicle Anatomy 0.000 claims description 4
- 201000010653 vesiculitis Diseases 0.000 claims description 4
- 230000001720 vestibular Effects 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 210000001789 adipocyte Anatomy 0.000 claims description 3
- 210000001130 astrocyte Anatomy 0.000 claims description 3
- 210000001011 carotid body Anatomy 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 210000001612 chondrocyte Anatomy 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 210000002808 connective tissue Anatomy 0.000 claims description 3
- 210000003298 dental enamel Anatomy 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 210000002768 hair cell Anatomy 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 210000004416 odontoblast Anatomy 0.000 claims description 3
- 210000004248 oligodendroglia Anatomy 0.000 claims description 3
- 210000000963 osteoblast Anatomy 0.000 claims description 3
- 210000002997 osteoclast Anatomy 0.000 claims description 3
- 210000000106 sweat gland Anatomy 0.000 claims description 3
- 210000001213 vestibule labyrinth Anatomy 0.000 claims description 3
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 claims description 2
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 102400000321 Glucagon Human genes 0.000 claims description 2
- 108060003199 Glucagon Proteins 0.000 claims description 2
- 102000003752 Lipocalin 1 Human genes 0.000 claims description 2
- 108010057281 Lipocalin 1 Proteins 0.000 claims description 2
- 102000018886 Pancreatic Polypeptide Human genes 0.000 claims description 2
- 102000005157 Somatostatin Human genes 0.000 claims description 2
- 108010056088 Somatostatin Proteins 0.000 claims description 2
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 210000002280 acid secreting cell Anatomy 0.000 claims description 2
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 210000002588 alveolar type II cell Anatomy 0.000 claims description 2
- 210000002947 bartholin's gland Anatomy 0.000 claims description 2
- 210000003651 basophil Anatomy 0.000 claims description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims description 2
- 210000003969 blast cell Anatomy 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000000233 bronchiolar non-ciliated Anatomy 0.000 claims description 2
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 2
- 210000000250 cementoblast Anatomy 0.000 claims description 2
- 210000001431 cementocyte Anatomy 0.000 claims description 2
- 210000002932 cholinergic neuron Anatomy 0.000 claims description 2
- 210000002987 choroid plexus Anatomy 0.000 claims description 2
- 230000001886 ciliary effect Effects 0.000 claims description 2
- 210000000399 corneal endothelial cell Anatomy 0.000 claims description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 210000005232 distal tubule cell Anatomy 0.000 claims description 2
- 210000000613 ear canal Anatomy 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- 210000005168 endometrial cell Anatomy 0.000 claims description 2
- 210000003979 eosinophil Anatomy 0.000 claims description 2
- 210000003386 epithelial cell of thymus gland Anatomy 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 210000003499 exocrine gland Anatomy 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 230000001434 glomerular Effects 0.000 claims description 2
- 210000001282 glomerular podocyte Anatomy 0.000 claims description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 2
- 229960004666 glucagon Drugs 0.000 claims description 2
- 210000002175 goblet cell Anatomy 0.000 claims description 2
- 230000002710 gonadal effect Effects 0.000 claims description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- 208000002557 hidradenitis Diseases 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940099472 immunoglobulin a Drugs 0.000 claims description 2
- 229940027941 immunoglobulin g Drugs 0.000 claims description 2
- 210000003990 interdental cell Anatomy 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims description 2
- 210000000554 iris Anatomy 0.000 claims description 2
- 210000004561 lacrimal apparatus Anatomy 0.000 claims description 2
- 210000001821 langerhans cell Anatomy 0.000 claims description 2
- 210000005265 lung cell Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 210000003593 megakaryocyte Anatomy 0.000 claims description 2
- 210000002752 melanocyte Anatomy 0.000 claims description 2
- 210000000716 merkel cell Anatomy 0.000 claims description 2
- 210000003584 mesangial cell Anatomy 0.000 claims description 2
- 210000005033 mesothelial cell Anatomy 0.000 claims description 2
- 210000000274 microglia Anatomy 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000001577 neostriatum Anatomy 0.000 claims description 2
- 210000004498 neuroglial cell Anatomy 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 210000004663 osteoprogenitor cell Anatomy 0.000 claims description 2
- 230000036407 pain Effects 0.000 claims description 2
- 230000000849 parathyroid Effects 0.000 claims description 2
- 210000003668 pericyte Anatomy 0.000 claims description 2
- 210000003446 pia mater Anatomy 0.000 claims description 2
- 210000001127 pigmented epithelial cell Anatomy 0.000 claims description 2
- 230000003169 placental effect Effects 0.000 claims description 2
- 210000004180 plasmocyte Anatomy 0.000 claims description 2
- 230000000272 proprioceptive effect Effects 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000005267 prostate cell Anatomy 0.000 claims description 2
- 210000000512 proximal kidney tubule Anatomy 0.000 claims description 2
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims description 2
- 210000004918 root sheath Anatomy 0.000 claims description 2
- 210000004116 schwann cell Anatomy 0.000 claims description 2
- 210000001732 sebaceous gland Anatomy 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 210000003728 serous cell Anatomy 0.000 claims description 2
- 210000000717 sertoli cell Anatomy 0.000 claims description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 210000001057 smooth muscle myoblast Anatomy 0.000 claims description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 2
- 229960000553 somatostatin Drugs 0.000 claims description 2
- 210000002325 somatostatin-secreting cell Anatomy 0.000 claims description 2
- 210000004500 stellate cell Anatomy 0.000 claims description 2
- 210000002437 synoviocyte Anatomy 0.000 claims description 2
- 210000001779 taste bud Anatomy 0.000 claims description 2
- 210000000108 taste bud cell Anatomy 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 210000004496 type 1 vestibular hair cell Anatomy 0.000 claims description 2
- 210000000637 type 2 vestibular hair cell Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 2
- 210000002395 vitreous cell Anatomy 0.000 claims description 2
- 210000001849 von ebner gland Anatomy 0.000 claims description 2
- 210000002934 adrenergic neuron Anatomy 0.000 claims 1
- 210000004504 adult stem cell Anatomy 0.000 claims 1
- 210000004081 cilia Anatomy 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 210000001706 olfactory mucosa Anatomy 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 210000002951 peptidergic neuron Anatomy 0.000 claims 1
- 210000004049 perilymph Anatomy 0.000 claims 1
- 210000005238 principal cell Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 description 116
- 206010052428 Wound Diseases 0.000 description 105
- 210000003491 skin Anatomy 0.000 description 42
- 230000029663 wound healing Effects 0.000 description 22
- 239000000243 solution Substances 0.000 description 19
- 230000006870 function Effects 0.000 description 17
- 230000008569 process Effects 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 230000012292 cell migration Effects 0.000 description 14
- 210000004207 dermis Anatomy 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 239000010949 copper Substances 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 229910052788 barium Inorganic materials 0.000 description 11
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 230000000737 periodic effect Effects 0.000 description 11
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 10
- 229910052802 copper Inorganic materials 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000017 hydrogel Substances 0.000 description 8
- 150000001768 cations Chemical class 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 6
- 230000037313 granulation tissue formation Effects 0.000 description 6
- 239000008279 sol Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229920001187 thermosetting polymer Polymers 0.000 description 6
- 102000029749 Microtubule Human genes 0.000 description 5
- 108091022875 Microtubule Proteins 0.000 description 5
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 239000012867 bioactive agent Substances 0.000 description 5
- 150000001718 carbodiimides Chemical class 0.000 description 5
- 239000002131 composite material Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 210000004688 microtubule Anatomy 0.000 description 5
- 239000004417 polycarbonate Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical group CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 description 4
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 229910001431 copper ion Inorganic materials 0.000 description 4
- 229920006037 cross link polymer Polymers 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 239000000806 elastomer Substances 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000012943 hotmelt Substances 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000003475 lamination Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 229920000515 polycarbonate Polymers 0.000 description 4
- 229920000867 polyelectrolyte Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000037309 reepithelialization Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012876 topography Methods 0.000 description 4
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 229920002101 Chitin Polymers 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004696 Poly ether ether ketone Substances 0.000 description 3
- 229930182556 Polyacetal Natural products 0.000 description 3
- 208000038016 acute inflammation Diseases 0.000 description 3
- 230000006022 acute inflammation Effects 0.000 description 3
- 229910001422 barium ion Inorganic materials 0.000 description 3
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229920002492 poly(sulfone) Polymers 0.000 description 3
- 229920001707 polybutylene terephthalate Polymers 0.000 description 3
- 229920002530 polyetherether ketone Polymers 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920006324 polyoxymethylene Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- XQUPVDVFXZDTLT-UHFFFAOYSA-N 1-[4-[[4-(2,5-dioxopyrrol-1-yl)phenyl]methyl]phenyl]pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1C(C=C1)=CC=C1CC1=CC=C(N2C(C=CC2=O)=O)C=C1 XQUPVDVFXZDTLT-UHFFFAOYSA-N 0.000 description 2
- 229920002943 EPDM rubber Polymers 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- 239000004697 Polyetherimide Substances 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 238000013475 authorization Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000254 ciliated cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 2
- 230000010393 epithelial cell migration Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000000059 patterning Methods 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920003192 poly(bis maleimide) Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 229920001601 polyetherimide Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 229920001955 polyphenylene ether Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000012815 thermoplastic material Substances 0.000 description 2
- 230000009772 tissue formation Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- KOMNUTZXSVSERR-UHFFFAOYSA-N 1,3,5-tris(prop-2-enyl)-1,3,5-triazinane-2,4,6-trione Chemical compound C=CCN1C(=O)N(CC=C)C(=O)N(CC=C)C1=O KOMNUTZXSVSERR-UHFFFAOYSA-N 0.000 description 1
- BJELTSYBAHKXRW-UHFFFAOYSA-N 2,4,6-triallyloxy-1,3,5-triazine Chemical compound C=CCOC1=NC(OCC=C)=NC(OCC=C)=N1 BJELTSYBAHKXRW-UHFFFAOYSA-N 0.000 description 1
- AUWOYLRSDMVESI-UHFFFAOYSA-N 2-(cyclohexyliminomethylideneamino)-n,n-diethylethanamine Chemical compound CCN(CC)CCN=C=NC1CCCCC1 AUWOYLRSDMVESI-UHFFFAOYSA-N 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2h-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- IGIJSFNBEUBMGB-UHFFFAOYSA-N 4-(cyclohexyliminomethylideneamino)-n,n-diethylcyclohexan-1-amine Chemical compound C1CC(N(CC)CC)CCC1N=C=NC1CCCCC1 IGIJSFNBEUBMGB-UHFFFAOYSA-N 0.000 description 1
- NWVVVQASZMXSCX-UHFFFAOYSA-N 4-[[4-(diethylamino)cyclohexyl]iminomethylideneamino]-n,n-diethylcyclohexan-1-amine Chemical compound C1CC(N(CC)CC)CCC1N=C=NC1CCC(N(CC)CC)CC1 NWVVVQASZMXSCX-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 239000004641 Diallyl-phthalate Substances 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 1
- FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920000028 Gradient copolymer Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000296380 Laminaria hyperborea Species 0.000 description 1
- 241001491708 Macrocystis Species 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920006169 Perfluoroelastomer Polymers 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004962 Polyamide-imide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004734 Polyphenylene sulfide Substances 0.000 description 1
- 229920002396 Polyurea Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 229920000180 alkyd Polymers 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 229920005603 alternating copolymer Polymers 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 108010054176 apotransferrin Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000010426 asphalt Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UMIVXZPTRXBADB-UHFFFAOYSA-N benzocyclobutene Chemical compound C1=CC=C2CCC2=C1 UMIVXZPTRXBADB-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003397 biobrane Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- QUDWYFHPNIMBFC-UHFFFAOYSA-N bis(prop-2-enyl) benzene-1,2-dicarboxylate Chemical compound C=CCOC(=O)C1=CC=CC=C1C(=O)OCC=C QUDWYFHPNIMBFC-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 108010089807 chitosanase Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011960 computer-aided design Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000004643 cyanate ester Substances 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- HQQADJVZYDDRJT-UHFFFAOYSA-N ethene;prop-1-ene Chemical group C=C.CC=C HQQADJVZYDDRJT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- IVJISJACKSSFGE-UHFFFAOYSA-N formaldehyde;1,3,5-triazine-2,4,6-triamine Chemical compound O=C.NC1=NC(N)=NC(N)=N1 IVJISJACKSSFGE-UHFFFAOYSA-N 0.000 description 1
- SLGWESQGEUXWJQ-UHFFFAOYSA-N formaldehyde;phenol Chemical compound O=C.OC1=CC=CC=C1 SLGWESQGEUXWJQ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- XPFVYQJUAUNWIW-UHFFFAOYSA-N furfuryl alcohol Chemical compound OCC1=CC=CO1 XPFVYQJUAUNWIW-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000067 inner hair cell Anatomy 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 210000004523 ligament cell Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229920003986 novolac Polymers 0.000 description 1
- 210000002560 odontocyte Anatomy 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920009441 perflouroethylene propylene Polymers 0.000 description 1
- 229920013653 perfluoroalkoxyethylene Polymers 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002493 poly(chlorotrifluoroethylene) Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920003055 poly(ester-imide) Polymers 0.000 description 1
- 229920001643 poly(ether ketone) Polymers 0.000 description 1
- 229920001652 poly(etherketoneketone) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920002312 polyamide-imide Polymers 0.000 description 1
- 229920001230 polyarylate Polymers 0.000 description 1
- 229920002577 polybenzoxazole Polymers 0.000 description 1
- 229920001692 polycarbonate urethane Polymers 0.000 description 1
- 239000005023 polychlorotrifluoroethylene (PCTFE) polymer Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- ODGAOXROABLFNM-UHFFFAOYSA-N polynoxylin Chemical compound O=C.NC(N)=O ODGAOXROABLFNM-UHFFFAOYSA-N 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000069 polyphenylene sulfide Polymers 0.000 description 1
- 229920001709 polysilazane Polymers 0.000 description 1
- 229940005642 polystyrene sulfonic acid Drugs 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229920001291 polyvinyl halide Polymers 0.000 description 1
- 229920006215 polyvinyl ketone Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- SCUZVMOVTVSBLE-UHFFFAOYSA-N prop-2-enenitrile;styrene Chemical compound C=CC#N.C=CC1=CC=CC=C1 SCUZVMOVTVSBLE-UHFFFAOYSA-N 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 229920003987 resole Polymers 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000018448 secretion by cell Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229920000638 styrene acrylonitrile Polymers 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000013460 sweaty Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 1
- 239000004634 thermosetting polymer Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000000515 tooth Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229920006305 unsaturated polyester Polymers 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009790 vascular invasion Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
-
- A61F13/01017—
-
- A61F13/01029—
-
- A61F13/01042—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive plasters or dressings
- A61F13/0203—Adhesive plasters or dressings having a fluid handling member
- A61F13/022—Adhesive plasters or dressings having a fluid handling member having more than one layer with different fluid handling characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/64—Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/009—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00314—Wound bandages with surface treatments
- A61F2013/00327—Wound bandages with surface treatments to create projections or depressions in surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
Abstract
Description
本願は、どちらも2015年4月23日に出願された米国特許出願第62/151875号及び同62/151936号、並びに2015年12月1日に出願された米国特許出願第62/261407号の利益を主張するものであり、これらを参照によりその全体を本明細書に援用する。
本発明は、国立衛生研究所によって認められた契約/認可番号1R43AR067584及び海軍/海軍研究局によって認められた契約/認可番号N000141310443の政府支援によって成された。米国政府は、本発明における権利を有する。
ポリジメチルシロキサンエラストマー(Xiameter RTV−4232−T2、Dow Corning;PDMSe)を凹形シリコンウエハ型で注型することによって、平滑(SM)及び微細パターン(+1.7SK2x2)試料を作製した。円形試料(d=20mm)を、細胞移動方向に平行に整列した特徴部を有する12ウェルプレートに付着させ、フィブロネクチン(15μg/mL終夜)で処理して、細胞接着を促進した。SM PDMSe矩形(5mmx20mm)を試料の中央に沿って配置して、改変引っかき検査を行った。ヒト表皮角化細胞(HEK:Human epidermal keratinocytes)を構成全体に1x104細胞/cm2で播き、完全角化細胞増殖培地(真皮細胞基本培地、0.4%ウシ下垂体抽出物、0.5ng/ml rh TGF−アルファ、6mM L−グルタミン、100ng/mlヒドロコルチゾン、5μg/mlインスリン、1μMエピネフリン、5μg/mlアポトランスフェリン、50U/mlペニシリン/ストレプトマイシン及び1μg/mlファンギゾン抗真菌剤)中で維持した。約70%コンフルエントにおいて、PDMSe矩形を除去して、空のパターン形成域を横切って細胞移動させた。移動を光学顕微鏡法で7日目までモニターした後、試料をCellTracker Orangeで染色し、固定した。創傷域の蛍光顕微鏡画像を取り、この領域内の細胞で覆われた平均面積をImageJソフトウェアによって計算した。
創傷治癒の複雑さの我々の知識の進化に従い、創傷被覆材市場もそれに応じて成長した。傷害は様々な程度に皮膚構造を損なうので、失われた皮膚を置き換える要求は、創傷のタイプ及び程度に大きく依存する。表面の創傷は、皮膚の最外層、すなわち表皮の喪失を招く。この層は、皮膚のバリア機能を維持し、角化細胞と呼ばれる上皮細胞から主になる。より重篤な傷害においては、表皮層、及び真皮の一部又は全部(例えば、それぞれ部分又は全層創傷)の喪失は、皮膚の完全性を回復するために2つの重要な組織タイプを交換又は再建する必要がある。真皮は、皮膚の機械的性質を担う結合組織である。それは、主に線維芽細胞及びその関連細胞外基質(ECM)で構成される。皮膚創傷治癒は、4つの正確に統合された段階、すなわち、止血、炎症、増殖及び再構築で進行する。創傷治癒が成功するには、4つの段階すべてが適切な順序及びタイミングで進行しなければならない。Sharklet微細パターン形成全層創傷処置は、増殖段階における2つの重要なステップ、すなわち血管新生と再上皮化を同時に促す最初の利用可能な被覆材である。
HEK移動分析からの最高性能Sharklet微細パターン(+10SK50x50)を創傷被覆材に適切なサイズにスケールアップし、ラットの確立された遅延治癒モデルにおいて試験して、広範な非治癒/慢性創傷に対する治癒挙動を確認した。創傷被覆材原型の最上層を上で概説した同じ手順に従って形成して、ゼラチンヒドロゲルを生成した。次いで、溶液を充填した型を4℃に1時間冷却して、ゼラチンを凝固させた。次に、2mlのCAPGEL(商標)スラリーを前述のように合成し、固体ゼラチンの上のPDMSe型(d=20mm)に充填した。最上ゼラチン層及び基底CAPGEL(商標)層を0.6M EDC及び0.2M NHSのPBS溶液で4℃で18時間化学的に架橋した。シリコーン型を構築物から除去し、6mm生検パンチを使用して、適切なサイズの被覆材を作製した。次いで、被覆材をPBSで1時間洗浄し、続いて24時間の間に10x食塩水クエン酸ナトリウム(SSC:saline sodium citrate)(20xSSC、Fisher BioReagants、脱イオン水で10xに希釈)を3回交換した。最後に、被覆材を24時間の間に生理食塩水を3回交換して洗浄し、続いて最終PBSリンス及び移植前に、Minncare滅菌剤(3%脱イオン水溶液)(Mar Cor、ミネソタ州プリマス)に10分間浸漬して滅菌した。
負傷後7日目のラット皮膚のH&E染色切片の代表的顕微鏡写真(図5b)の定性的評価は、二層被覆材で処置した創傷では無処置対照に比べて治癒結果が改善した徴候を示す。無処置創傷は、概して、無傷の皮膚に比べて、より高レベルの収縮、不完全な再上皮化、及び皮膚構造の相違を示した(図5c)。両方の二層被覆材構築物は、無処置又はEndoform処置創傷に比べて、より完全な再上皮化、拘縮の減少を示し、天然の皮膚により近い真皮再生を示した(図5d及び5e)。臨床利用可能な皮膚テンプレート被覆材Endoformで処置した創傷は、二層構築物で被覆したものよりも収縮レベルが高く、不完全な上皮化を示し、7日目の肉芽組織形成の量及び完成度が低下した(図5f)。
Claims (56)
- 第1の層であって、創傷の血管新生を促進するチャネルを含む前記第1の層と、
前記第1の層に接する第2の層であって、前記第1の層と同じ又は異なる化学組成を有し、テクスチャを有する少なくとも1つの表面を含み、前記テクスチャの方向が細胞配向及び増殖を促進するのに有効である、前記第2の層と、
を含む、多層創傷被覆材。 - 前記第1の層が、前記創傷が位置する患者の解剖学的組織に相補的なテクスチャを有する表面を含む、請求項1に記載の多層創傷被覆材。
- 前記第1の層と前記第2の層が互いに直接接する、請求項1に記載の多層創傷被覆材。
- 前記第1の層及び前記第2の層が熱可塑性層である、請求項1に記載の多層創傷被覆材。
- 前記第1の層及び前記第2の層が生分解性層である、請求項1に記載の多層創傷被覆材。
- 前記第1の層及び前記第2の層が生体適合性層である、請求項1に記載の多層創傷被覆材。
- 前記第1の層が架橋層である、請求項1に記載の多層創傷被覆材。
- 前記第2の層が架橋層である、請求項1に記載の多層創傷被覆材。
- 前記第1の層及び前記第2の層が、ポリ乳酸グリコール酸(PLGA)、ポリ−カプロラクトン(PCL)、ポリ乳酸グリコール酸とポリ−カプロラクトンのコポリマー(PCL−PLGAコポリマー)、ポリヒドロキシ酪酸吉草酸(PHBV)、ポリオルトエステル(POE)、ポリエチレンオキシド−ブチレンテレフタラート(PEO−PBTP)、ポリ−D,L−乳酸−p−ジオキサノン−ポリエチレングリコールブロックコポリマー(PLA−DX−PEG)又は上記ポリマーの少なくとも1種を含む組合せを含む、請求項1に記載の多層創傷被覆材。
- 前記第1の層及び前記第2の層が、ポリウレタンとポリ乳酸のコポリマー又はポリウレタンとポリ乳酸グリコール酸のコポリマーを含む、請求項1に記載の多層創傷被覆材。
- 前記第2の層の少なくとも1つの表面の前記テクスチャが複数の離隔した特徴部(feature)を含み、各特徴部が、近傍の特徴部とは実質的に異なる形状を有し、前記複数の離隔した特徴部が複数のグループで配列され、前記グループ各々の中の前記離隔した特徴部が平均距離約10ナノメートル〜約200マイクロメートルで離隔しており、隣接する特徴部のグループが互いに離隔されて中間蛇行経路を画定する、請求項1に記載の多層創傷被覆材。
- ポリマー材料の第1の層を形成するステップと、
前記第1の層と同じポリマー材料の第2の層を前記第1の層の上に形成するステップと、
前記第1の層と同じポリマー材料の前記第2の層のテクスチャード表面を形成するステップであって、前記テクスチャード表面が、創傷被覆材に使用されたときに方向性の細胞増殖を促進するのに有効である、ステップとを含み、
前記第1の層及び前記第2の層が積層造形プロセスによって形成される、
方法。 - 前記第1の層及び前記第2の層が3次元印刷積層造形プロセスによって形成される、請求項12に記載の方法。
- 創傷が位置する患者の表皮の解剖学的組織の3次元コンピュータモデルを作成するステップと、
前記第1の層と同じポリマー材料の前記第1の層のテクスチャード表面を形成するステップであって、前記テクスチャード表面が前記3次元コンピュータモデルに相補的であるステップと
を更に含む、請求項12に記載の方法。 - 前記第1の層がチャネルを含む、請求項12に記載の方法。
- 前記第2の層の少なくとも1つの表面の前記テクスチャが複数の離隔した特徴部を含み、各特徴部が、近傍の特徴部とは実質的に異なる形状を有し、前記複数の離隔した特徴部が複数のグループで配列され、前記グループ各々の中の前記離隔した特徴部が平均距離約10ナノメートル〜約200マイクロメートルで離隔しており、隣接する特徴部のグループが互いに離隔されて中間蛇行経路を画定する、請求項12に記載の方法。
- 前記第1の層及び前記第2の層が、ポリ乳酸グリコール酸(PLGA)、ポリ−カプロラクトン(PCL)、ポリ乳酸グリコール酸とポリ−カプロラクトンのコポリマー(PCL−PLGAコポリマー)、ポリヒドロキシ酪酸吉草酸(PHBV)、ポリオルトエステル(POE)、ポリエチレンオキシド−ブチレンテレフタラート(PEO−PBTP)、ポリ−D,L−乳酸−p−ジオキサノン−ポリエチレングリコールブロックコポリマー(PLA−DX−PEG)又は上記ポリマーの少なくとも1種を含む組合せを含む、請求項12に記載の方法。
- 前記第1の層及び前記第2の層が、ポリウレタンとポリ乳酸のコポリマー又はポリウレタンとポリ乳酸グリコール酸のコポリマーを含む、請求項12に記載の方法。
- 前記第1の層及び前記第2の層が生分解性層である、請求項12に記載の方法。
- 多層創傷被覆材を創傷の上又は中に配置するステップ
を含み、
前記多層被覆材が、
第1のゲル層であって、創傷被覆材に使用されたときに血管新生を促進するチャネルを含む前記第1のゲル層と、
前記第1のゲル層に接する第2の層であって、テクスチャを有する少なくとも1つの表面を含む前記第2の層とを含み、前記チャネル及び前記テクスチャが1つ以上の方向の多層細胞増殖を促進する、
方法。 - 前記第1のゲル層と前記第2の層が互いに直接接する、請求項21に記載の方法。
- 前記第1のゲル層が架橋層である、請求項21に記載の方法。
- 前記第2の層が架橋層である、請求項21に記載の方法。
- 前記第2の層が熱可塑性層である、請求項21に記載の方法。
- 前記第1の層及び前記第2の層が架橋ゼラチンを含む、請求項21に記載の方法。
- 前記第1の層がゼラチン、コラーゲン、キトサン、アルギナート又はそれらの組合せを含む、請求項21に記載の方法。
- 前記第2の層がゼラチン、コラーゲン、キトサン、アルギナート又はそれらの組合せを含む、請求項21に記載の方法。
- 前記第2の層が、ポリ乳酸グリコール酸(PLGA)、ポリ−カプロラクトン(PCL)、ポリ乳酸グリコール酸とポリ−カプロラクトンのコポリマー(PCL−PLGAコポリマー)、ポリヒドロキシ酪酸吉草酸(PHBV)、ポリオルトエステル(POE)、ポリエチレンオキシド−ブチレンテレフタラート(PEO−PBTP)、ポリ−D,L−乳酸−p−ジオキサノン−ポリエチレングリコールブロックコポリマー(PLA−DX−PEG)、又は上記生分解性ポリマーの少なくとも1種を含む組合せを含む、請求項25に記載の方法。
- 前記第2の層が、ポリウレタンとポリ乳酸のコポリマー又はポリウレタンとポリ乳酸グリコール酸のコポリマーを含む、請求項25に記載の方法。
- 前記テクスチャが複数の離隔した特徴部を含み、各特徴部が、近傍の特徴部とは実質的に異なる形状を有し、前記複数の離隔した特徴部が複数のグループで配列され、前記グループ各々の中の前記離隔した特徴部が平均距離約10ナノメートル〜約200マイクロメートルで離隔しており、隣接する特徴部のグループが互いに離隔されて中間蛇行経路を画定する、請求項1に記載の方法。
- 第1のゲル層であって、創傷被覆材に使用されたときに血管新生を促進するチャネルを含み、前記第1の層が第1のタイプの増殖細胞を含む、前記第1のゲル層と、
前記第1のゲル層に接する第2の層であって、テクスチャを有する少なくとも1つの表面を含み、第2のタイプの増殖細胞を含む、前記第2の層と
を含む、物品。 - 前記第1の層と前記第2の層がどちらも同じゲルを含む、請求項32に記載の物品。
- 前記第1の層がチャネルを含み、前記第1のタイプの増殖細胞が前記チャネル中に存在する、請求項32に記載の物品。
- 前記第2のタイプの増殖細胞が前記テクスチャ上に配置された、請求項32に記載の物品。
- 前記第1のタイプの増殖細胞が前記第2のタイプの増殖細胞と同じである、請求項32に記載の物品。
- 前記第1のタイプの増殖細胞が、胚性幹細胞、成体幹細胞、芽細胞、クローン細胞、受精卵、胎盤細胞、角化細胞、表皮基底細胞、毛幹細胞、毛根鞘細胞、表面上皮細胞、基底上皮細胞、尿上皮細胞、唾液腺細胞、粘液細胞、漿液細胞、フォンエブネル腺細胞、乳腺細胞、涙腺細胞、耳道腺細胞、エクリン汗腺細胞、アポクリン汗腺細胞、モル腺細胞、皮脂腺細胞、ボウマン腺細胞、ブルンネル腺細胞、精嚢細胞、前立腺細胞、尿道球腺細胞、バルトリン腺細胞、リトル腺細胞、子宮内膜細胞、気道又は消化管の杯細胞、胃の粘液細胞、胃腺の酵素原細胞、胃腺の酸分泌細胞、インスリン産生β細胞、グルカゴン産生α細胞、ソマトスタチン産生δ細胞、膵ポリペプチド産生細胞、膵管細胞、小腸のパネート細胞、肺のII型肺胞上皮細胞、肺のクララ細胞、下垂体前葉細胞、下垂体中葉細胞、下垂体後葉細胞、腸管又は気道のホルモン分泌細胞、甲状腺細胞、副甲状腺細胞、副腎細胞、性腺細胞、腎臓の傍糸球体細胞、腎臓の緻密斑細胞、腎臓の周血管極細胞、腎臓のメサンギウム細胞、腸の刷子縁細胞、外分泌腺の線条部導管、胆嚢上皮細胞、腎臓の近位尿細管の刷子縁細胞、腎臓の遠位尿細管細胞、輸出管の無繊毛細胞、精巣上体主細胞、精巣上体基底細胞、肝細胞(hepatacyte)、脂肪細胞、I型肺細胞、膵管細胞、汗腺の非線条部導管細胞、唾液腺の非線条部導管細胞、乳腺の非線条部導管細胞、腎糸球体の壁細胞、腎糸球体の足細胞、ヘンレ係蹄の薄いセグメントの細胞、集合管細胞、精嚢の導管細胞、前立腺の導管細胞、血管内皮細胞、滑膜細胞、漿膜細胞、耳の外リンパ腔を覆う扁平細胞、耳の内リンパ腔を覆う細胞、脈絡叢細胞、軟膜くも膜の扁平細胞、眼の毛様体上皮細胞、角膜内皮細胞、推進機能を有する繊毛細胞、エナメル芽細胞、耳の前庭器の半月面細胞、コルチ器の歯間細胞、線維芽細胞、血液流路の周細胞、椎間板の髄核細胞、セメント芽細胞(cementoblast)、セメント細胞(cementocyte)、象牙芽細胞、象牙細胞(odontocyte)、軟骨細胞、骨芽細胞、骨細胞、骨芽前駆細胞、眼の硝子体の硝子体細胞、耳の外リンパ腔の星細胞、骨格筋細胞、心筋細胞、平滑筋細胞、筋上皮細胞、赤血球、巨核球、単球、結合組織マクロファージ、ランゲルハンス細胞、破骨細胞、樹状細胞、小膠細胞、好中球、好酸球、好塩基球、肥満細胞、形質細胞、ヘルパーT細胞、サプレッサーT細胞、キラーT細胞、免疫グロブリンM、免疫グロブリンG、免疫グロブリンA、免疫グロブリンE、キラー細胞、桿体細胞、錐体細胞、コルチ器の内有毛細胞、コルチ器の外有毛細胞、耳の前庭器のI型有毛細胞、耳の前庭器のII型有毛細胞、II型味蕾細胞、嗅神経細胞、嗅上皮の基底細胞、I型頚動脈小体細胞、Ii型頚動脈小体細胞、メルケル細胞、触覚専用の一次感覚神経、温度専用の一次感覚神経、疼痛専用の一次神経、固有受容性一次感覚神経、自律神経系のコリン作動性神経細胞、自律神経系のアドレナリン作動性神経細胞、自律神経系のペプチド作動性神経細胞、コルチ器の内柱細胞、コルチ器の外柱細胞、コルチ器の内指節細胞、コルチ器の外指節細胞、辺縁細胞、ヘンゼン細胞、前庭器の支持細胞、味蕾の支持細胞、嗅上皮の支持細胞、シュワン細胞、衛星細胞、腸管グリア細胞、中枢神経系の神経細胞、中枢神経系の星状細胞、中枢神経系の乏突起膠細胞、前水晶体上皮細胞、水晶体線維細胞、メラニン細胞、網膜色素上皮細胞、虹彩色素上皮細胞、卵原細胞、卵母細胞、***細胞、精原細胞、卵胞細胞、セルトリ細胞及び胸腺上皮細胞又はそれらの組合せからなる群から選択される、請求項36に記載の物品。
- 前記第1のタイプの増殖細胞が前記第2のタイプの増殖細胞とは異なる、請求項32に記載の物品。
- 第1のゲル層であって、前記第1の層が、創傷の血管新生を促進する3次元チャネルを含み、天然又は合成生分解性ポリマーを含む、前記第1のゲル層と、
前記第1のゲル層に接する第2の層であって、テクスチャを有する少なくとも1つの表面を含み、前記テクスチャの方向が細胞配向及び増殖を促進するのに有効である、前記第2の層と
を含む、多層創傷被覆材。 - 前記多層創傷被覆材が、前記創傷が位置する患者の解剖学的組織に相補的であるサイズ及び形状を有する表面を含む、請求項39に記載の多層創傷被覆材。
- 前記第1の層と前記第2の層が互いに直接接する、請求項39に記載の多層創傷被覆材。
- 前記第1の層及び前記第2の層が熱可塑性層である、請求項39に記載の多層創傷被覆材。
- 前記第1の層及び前記第2の層が生分解性層である、請求項39に記載の多層創傷被覆材。
- 前記第1の層及び前記第2の層が生体適合性層である、請求項39に記載の多層創傷被覆材。
- 前記第1の層が架橋層である、請求項39に記載の多層創傷被覆材。
- 前記第2の層が架橋層である、請求項39に記載の多層創傷被覆材。
- 前記第1の層及び/又は前記第2の層が、ポリ乳酸グリコール酸(PLGA)、ポリ−カプロラクトン(PCL)、ポリ乳酸グリコール酸とポリ−カプロラクトンのコポリマー(PCL−PLGAコポリマー)、ポリヒドロキシ酪酸吉草酸(PHBV)、ポリオルトエステル(POE)、ポリエチレンオキシド−ブチレンテレフタラート(PEO−PBTP)、ポリ−D,L−乳酸−p−ジオキサノン−ポリエチレングリコールブロックコポリマー(PLA−DX−PEG)又は上記ポリマーの少なくとも1種を含む組合せを含む、請求項39に記載の多層創傷被覆材。
- 前記第1の層及び/又は前記第2の層が、ポリウレタンとポリ乳酸のコポリマー又はポリウレタンとポリ乳酸グリコール酸のコポリマーを含む、請求項39に記載の多層創傷被覆材。
- 前記第2の層の少なくとも1つの表面の前記テクスチャが複数の離隔した特徴部を含み、各特徴部が、近傍の特徴部とは実質的に異なる形状を有し、前記複数の離隔した特徴部が複数のグループで配列され、前記グループ各々の中の前記離隔した特徴部が平均距離約10ナノメートル〜約200マイクロメートルで離隔しており、隣接する特徴部のグループが互いに離隔されて中間蛇行経路を画定する、請求項39に記載の多層創傷被覆材。
- 天然又は合成生分解性ポリマー材料の第1の層を形成するステップと、
ポリマー材料の第2の層を前記第1の層の上に形成するステップと、
前記第2の層のテクスチャード表面を形成するステップであって、前記テクスチャード表面が、創傷被覆材に使用されたときに方向性の細胞増殖を促進するのに有効である、ステップと
を含み、
前記第1の層及び前記第2の層が積層造形プロセスによって形成される、
方法。 - 前記第1の層及び前記第2の層が3次元印刷積層造形プロセスによって形成される、請求項50に記載の方法。
- 創傷が位置する患者の解剖学的組織の3次元コンピュータモデルを作成するステップと、
ポリマー材料の前記第1の層の表面を形成するステップであって、前記表面のサイズ及び形状が前記3次元コンピュータモデルに相補的であるステップと
を更に含む、請求項50に記載の方法。 - 前記第1の層が3次元チャネルを含む、請求項50に記載の方法。
- 前記第2の層の少なくとも1つの表面の前記テクスチャが複数の離隔した特徴部を含み、各特徴部が、近傍の特徴部とは実質的に異なる形状を有し、前記複数の離隔した特徴部が複数のグループで配列され、前記グループ各々の中の前記離隔した特徴部が平均距離約10ナノメートル〜約200マイクロメートルで離隔しており、隣接する特徴部のグループが互いに離隔されて中間蛇行経路を画定する、請求項50に記載の方法。
- 前記第1の層及び前記第2の層が、ポリ乳酸グリコール酸(PLGA)、ポリ−カプロラクトン(PCL)、ポリ乳酸グリコール酸とポリ−カプロラクトンのコポリマー(PCL−PLGAコポリマー)、ポリヒドロキシ酪酸吉草酸(PHBV)、ポリオルトエステル(POE)、ポリエチレンオキシド−ブチレンテレフタラート(PEO−PBTP)、ポリ−D,L−乳酸−p−ジオキサノン−ポリエチレングリコールブロックコポリマー(PLA−DX−PEG)又は上記ポリマーの少なくとも1種を含む組合せを含む、請求項50に記載の方法。
- 前記第1の層及び前記第2の層が、ポリウレタンとポリ乳酸のコポリマー又はポリウレタンとポリ乳酸グリコール酸のコポリマーを含む、請求項50に記載の方法。
- 前記第1の層及び前記第2の層が生分解性層である、請求項50に記載の方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562151875P | 2015-04-23 | 2015-04-23 | |
US201562151936P | 2015-04-23 | 2015-04-23 | |
US62/151,875 | 2015-04-23 | ||
US62/151,936 | 2015-04-23 | ||
US201562261407P | 2015-12-01 | 2015-12-01 | |
US62/261,407 | 2015-12-01 | ||
PCT/US2016/029122 WO2017011050A2 (en) | 2015-04-23 | 2016-04-25 | Bilayered devices for enhanced healing |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2018512959A true JP2018512959A (ja) | 2018-05-24 |
Family
ID=57757599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017554554A Pending JP2018512959A (ja) | 2015-04-23 | 2016-04-25 | 治癒向上のための二層デバイス |
Country Status (9)
Country | Link |
---|---|
US (1) | US11458042B2 (ja) |
EP (1) | EP3285783B1 (ja) |
JP (1) | JP2018512959A (ja) |
KR (1) | KR20170140315A (ja) |
CN (1) | CN107847633B (ja) |
AU (1) | AU2016294135A1 (ja) |
CA (1) | CA2983292A1 (ja) |
HK (1) | HK1250220A1 (ja) |
WO (1) | WO2017011050A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022505767A (ja) * | 2018-10-24 | 2022-01-14 | ソムニオ グローバル ホールディングス,エルエルシー | 機能的な創傷治療ドレッシング材 |
JP2022113662A (ja) * | 2021-01-25 | 2022-08-04 | ウルトラ ヴイ カンパニー リミテッド | フィラー用生分解性高分子微粒子、これを含むフィラー用凍結乾燥体、その製造方法及び前記凍結乾燥体を含むフィラー用注射剤 |
KR102439335B1 (ko) * | 2021-12-10 | 2022-09-02 | 주식회사 엠케이바이오텍 | 태반-유래 줄기세포를 함유하는 피부 재생용 바이오패치형 세포치료제 |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0808376D0 (en) | 2008-05-08 | 2008-06-18 | Bristol Myers Squibb Co | Wound dressing |
GB0817796D0 (en) | 2008-09-29 | 2008-11-05 | Convatec Inc | wound dressing |
AU2009314119B2 (en) | 2008-11-11 | 2016-03-03 | University Of Florida Research Foundation, Inc. | Method of patterning a surface and articles comprising the same |
GB201020236D0 (en) | 2010-11-30 | 2011-01-12 | Convatec Technologies Inc | A composition for detecting biofilms on viable tissues |
WO2012078781A1 (en) | 2010-12-08 | 2012-06-14 | Convatec Technologies Inc. | Integrated system for assessing wound exudates |
US9526816B2 (en) | 2010-12-08 | 2016-12-27 | Convatec Technologies Inc. | Wound exudate monitor accessory |
US9937655B2 (en) | 2011-06-15 | 2018-04-10 | University Of Florida Research Foundation, Inc. | Method of manufacturing catheter for antimicrobial control |
GB201115182D0 (en) | 2011-09-02 | 2011-10-19 | Trio Healthcare Ltd | Skin contact material |
GB2497406A (en) | 2011-11-29 | 2013-06-12 | Webtec Converting Llc | Dressing with a perforated binder layer |
KR20150099776A (ko) | 2012-12-20 | 2015-09-01 | 컨바텍 테크놀러지스 인크 | 화학적 개질된 셀룰로스 섬유의 처리 |
EP3177354A4 (en) | 2014-08-07 | 2018-03-07 | Sharklet Technologies, Inc. | Patterns for flow control and bioadhesion control |
CN109310528B (zh) | 2016-03-30 | 2021-07-20 | 康沃特克科技公司 | 检测伤口中的微生物感染 |
KR20190008199A (ko) | 2016-03-30 | 2019-01-23 | 시노보 게엠베하 | 상처에서 미생물 감염의 검출 방법 |
EP3481360B1 (en) | 2016-07-08 | 2022-03-09 | ConvaTec Technologies Inc. | Fluid flow sensing |
WO2018009873A1 (en) | 2016-07-08 | 2018-01-11 | Convatec Technologies Inc. | Fluid collection apparatus |
ES2882336T3 (es) | 2016-07-08 | 2021-12-01 | Convatec Technologies Inc | Sistema flexible de presión negativa |
US11465332B2 (en) | 2016-09-20 | 2022-10-11 | Sharklet Technologies, Inc. | Imprinting tape, method of manufacture thereof and articles comprising the same |
EP3515680A4 (en) | 2016-09-20 | 2020-06-03 | Sharklet Technologies, Inc. | MATRIX FOR THE CONTINUOUS MANUFACTURE OF TEXTURED SURFACES AND METHODS OF MANUFACTURE THEREOF |
US20200054875A1 (en) * | 2017-02-13 | 2020-02-20 | University Of Florida Research Foundation, Incorporated | Sharklet topographies to control neutral cell interactions with implanted electrodes |
CN114795657B (zh) * | 2017-05-10 | 2023-07-14 | 墨尼克医疗用品有限公司 | 伤口处理中的复合泡沫 |
US11376005B2 (en) | 2017-05-24 | 2022-07-05 | University Of Florida Research Foundation, Incorporated | Tissue-engineered electronic peripheral nerve interface |
US11510877B2 (en) * | 2017-10-10 | 2022-11-29 | Capsugel Belgium Nv | Gelling multiparticulates |
BR112020016593B1 (pt) * | 2018-02-15 | 2023-11-14 | Biom'up France SAS | Produto hemostático impresso, uso de fluido hemostático e método de fabricação de produtos hemostáticos |
US11717991B2 (en) | 2018-03-20 | 2023-08-08 | Sharklet Technologies, Inc. | Molds for manufacturing textured articles, methods of manufacturing thereof and articles manufactured therefrom |
US20210213703A1 (en) * | 2018-05-16 | 2021-07-15 | Sharklet Technologies, Inc. | Textured surfaces having variable amounts of surface energy, methods of manufacture thereof and articles comprising the same |
CN109731130B (zh) * | 2018-11-14 | 2021-09-24 | 华中科技大学同济医学院附属协和医院 | 一种低温生物3d打印技术制备水凝胶创面敷料的方法 |
JP2022516123A (ja) * | 2018-12-28 | 2022-02-24 | エクセル メッド、エルエルシー | バイオロジカルスキャホールド及びその製造方法 |
EP3975926A1 (en) * | 2019-05-31 | 2022-04-06 | W.L. Gore & Associates, Inc. | A biocompatible membrane composite |
WO2020252448A1 (en) * | 2019-06-13 | 2020-12-17 | Sharklet Technologies, Inc. | Method for accelerated production of electroform tooling inserts |
KR102283464B1 (ko) * | 2019-06-28 | 2021-08-02 | 경북대학교 산학협력단 | Vegf 펩타이드를 포함하는 하이드로겔 기반 창상 피복재 및 이의 제조방법 |
US11771819B2 (en) | 2019-12-27 | 2023-10-03 | Convatec Limited | Low profile filter devices suitable for use in negative pressure wound therapy systems |
US11331221B2 (en) | 2019-12-27 | 2022-05-17 | Convatec Limited | Negative pressure wound dressing |
CN111632187B (zh) * | 2020-06-12 | 2021-05-18 | 安徽农业大学 | 一种生物可降解医用敷料及其制备方法 |
CN111825859A (zh) * | 2020-07-23 | 2020-10-27 | 陕西科技大学 | 一种具有自修复功能的仿生电子皮肤医用支架材料及其制备方法 |
KR102448385B1 (ko) * | 2020-08-10 | 2022-09-29 | 김인석 | 발치와 충전용 충전재 및 발치와 충전용 충전재 키트 |
CN113368295B (zh) * | 2021-06-07 | 2022-04-15 | 北京科技大学 | 一种定向排出渗液的抗菌大变形定制化敷料的制备方法 |
CN113616420B (zh) * | 2021-08-06 | 2023-03-31 | 周建大 | 抑菌铜基合金功能性复合敷料 |
CN114474708A (zh) * | 2021-09-16 | 2022-05-13 | 兰州大学 | 一种用于压电促愈合型伤口敷料制备的3d打印技术 |
CN116099056A (zh) * | 2023-04-07 | 2023-05-12 | 云南云科特色植物提取实验室有限公司 | 一种含仿生纹理结构的人工皮肤及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07136240A (ja) * | 1993-11-12 | 1995-05-30 | Kuraray Co Ltd | アルギン酸塩集合体を使用した創傷被覆材 |
JP2003305067A (ja) * | 2002-04-12 | 2003-10-28 | Gunze Ltd | 真皮再生用基材 |
JP2006504465A (ja) * | 2002-10-29 | 2006-02-09 | バイオポル カンパニー リミテッド | 充填型ポリウレタンフォームドレッシング材およびその製造方法 |
WO2008070625A2 (en) * | 2006-12-05 | 2008-06-12 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
WO2009122710A1 (ja) * | 2008-03-31 | 2009-10-08 | 富士フイルム株式会社 | 医療用組成物 |
WO2012122105A1 (en) * | 2011-03-07 | 2012-09-13 | Wake Forest University Health Sciences | Delivery system |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030225355A1 (en) * | 1998-10-01 | 2003-12-04 | Butler Charles E. | Composite material for wound repair |
AU2001261465A1 (en) * | 2000-05-12 | 2001-11-26 | The Regents Of The University Of Michigan | Reverse fabrication of porous materials |
US7041868B2 (en) | 2000-12-29 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Bioabsorbable wound dressing |
US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
EP1404508A1 (de) | 2001-06-21 | 2004-04-07 | Bernd Späth | Körper mit verbesserten oberflächen-eigenschaften |
WO2004005533A2 (en) | 2002-07-10 | 2004-01-15 | University Of Florida | Sol-gel derived bioactive glass polymer composite |
US7143709B2 (en) | 2004-02-17 | 2006-12-05 | University Of Florida Research Foundation, Inc. | Surface topography for non-toxic bioadhesion control |
US9016221B2 (en) * | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
US7117807B2 (en) | 2004-02-17 | 2006-10-10 | University Of Florida Research Foundation, Inc. | Dynamically modifiable polymer coatings and devices |
WO2005087287A1 (en) | 2004-03-05 | 2005-09-22 | University Of Florida Research Foundation Inc. | Novel tissue engineered scaffolds derived from copper capillary alginate gels |
EP1951149A4 (en) | 2005-11-07 | 2011-03-16 | Massachusetts Inst Technology | GRADIENT MATRIZE FOR ANGIOGENESIS IN THE REGENERATION OF BIG ORGANS |
AU2009314119B2 (en) | 2008-11-11 | 2016-03-03 | University Of Florida Research Foundation, Inc. | Method of patterning a surface and articles comprising the same |
US9943402B2 (en) | 2008-11-20 | 2018-04-17 | Insight Innovations, Llc | Micropatterned intraocular implant |
US20120232649A1 (en) | 2008-11-20 | 2012-09-13 | Insight Innovations, Llc | Intraocular Lens Cell Migration Inhibition System |
US9045651B2 (en) * | 2010-06-22 | 2015-06-02 | University Of Florida Research Foundation, Inc. | Antifouling surfaces, methods of manufacture thereof and articles comprising the same |
US9937655B2 (en) | 2011-06-15 | 2018-04-10 | University Of Florida Research Foundation, Inc. | Method of manufacturing catheter for antimicrobial control |
US20130017227A1 (en) * | 2011-07-15 | 2013-01-17 | Lambert Jr Cary Jake | Wound healing compositions and associated methods |
US20140336557A1 (en) * | 2013-05-10 | 2014-11-13 | Biovation Ii, Llc | Biopolymer multi-layer multi-functional medical dressing and method of making same |
US9545302B2 (en) | 2013-11-20 | 2017-01-17 | Dermagenesis Llc | Skin printing and auto-grafting |
CN103961749B (zh) * | 2014-05-07 | 2015-09-16 | 无锡贝迪生物工程有限公司 | 一种制备胶原蛋白/硅胶膜双层支架的方法 |
US10221274B2 (en) | 2014-06-25 | 2019-03-05 | University Of Florida Research Foundation, Incorporated | Polyurethanes, articles comprising the same and methods of manufacture thereof |
EP3177354A4 (en) | 2014-08-07 | 2018-03-07 | Sharklet Technologies, Inc. | Patterns for flow control and bioadhesion control |
CN104208041B (zh) * | 2014-08-28 | 2018-12-21 | 上海赛琅医药科技有限公司 | 一种用于预防、干预疤痕以及疤痕增生的可塑性硅凝胶和其制作方法 |
US9903792B2 (en) | 2014-10-30 | 2018-02-27 | Sharklet Technologies, Inc. | Ventilator-endotracheal tube-lung benchtop model |
EP3303116A4 (en) | 2015-06-03 | 2019-02-27 | Sharklet Technologies, Inc. | SURFACE OPOGRAPHS FOR THE NON-INFERTIVE COMBUSTION OF BIOADHESION |
EP3328454A4 (en) | 2015-07-30 | 2019-03-20 | Sharklet Technologies, Inc. | TEXTURED ARTICLES FOR ENHANCED CELL FORMATION AND METHODS OF MAKING SAME |
CN109790404B (zh) | 2016-05-20 | 2021-12-14 | 佛罗里达大学研究基金会公司 | 新型raft聚合防污技术 |
US11465332B2 (en) | 2016-09-20 | 2022-10-11 | Sharklet Technologies, Inc. | Imprinting tape, method of manufacture thereof and articles comprising the same |
EP3515680A4 (en) | 2016-09-20 | 2020-06-03 | Sharklet Technologies, Inc. | MATRIX FOR THE CONTINUOUS MANUFACTURE OF TEXTURED SURFACES AND METHODS OF MANUFACTURE THEREOF |
US11717991B2 (en) | 2018-03-20 | 2023-08-08 | Sharklet Technologies, Inc. | Molds for manufacturing textured articles, methods of manufacturing thereof and articles manufactured therefrom |
-
2016
- 2016-04-25 CN CN201680036563.3A patent/CN107847633B/zh active Active
- 2016-04-25 CA CA2983292A patent/CA2983292A1/en not_active Abandoned
- 2016-04-25 WO PCT/US2016/029122 patent/WO2017011050A2/en active Application Filing
- 2016-04-25 EP EP16824826.8A patent/EP3285783B1/en active Active
- 2016-04-25 AU AU2016294135A patent/AU2016294135A1/en not_active Abandoned
- 2016-04-25 KR KR1020177033865A patent/KR20170140315A/ko unknown
- 2016-04-25 US US15/568,767 patent/US11458042B2/en active Active
- 2016-04-25 JP JP2017554554A patent/JP2018512959A/ja active Pending
-
2018
- 2018-07-26 HK HK18109716.4A patent/HK1250220A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07136240A (ja) * | 1993-11-12 | 1995-05-30 | Kuraray Co Ltd | アルギン酸塩集合体を使用した創傷被覆材 |
JP2003305067A (ja) * | 2002-04-12 | 2003-10-28 | Gunze Ltd | 真皮再生用基材 |
JP2006504465A (ja) * | 2002-10-29 | 2006-02-09 | バイオポル カンパニー リミテッド | 充填型ポリウレタンフォームドレッシング材およびその製造方法 |
WO2008070625A2 (en) * | 2006-12-05 | 2008-06-12 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
WO2009122710A1 (ja) * | 2008-03-31 | 2009-10-08 | 富士フイルム株式会社 | 医療用組成物 |
WO2012122105A1 (en) * | 2011-03-07 | 2012-09-13 | Wake Forest University Health Sciences | Delivery system |
Non-Patent Citations (2)
Title |
---|
"Biogradable,micropatterned wound dressings for enhanced epithelialization", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY MAR 22 2015 CONF- 249TH NATIONAL MEETING AND EXPOSITIO, JPN6020003307, 22 March 2015 (2015-03-22), ISSN: 0004359228 * |
"The roles of knitted mesh-reinforced collagen-chitosan hybrid scaffold in the one-step repair of ful", ACTA BIOMATERIALIA, vol. 9, JPN6020003310, 2013, pages 7822 - 7832, ISSN: 0004359229 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022505767A (ja) * | 2018-10-24 | 2022-01-14 | ソムニオ グローバル ホールディングス,エルエルシー | 機能的な創傷治療ドレッシング材 |
JP7419362B2 (ja) | 2018-10-24 | 2024-01-22 | ソムニオ グローバル ホールディングス,エルエルシー | 機能的な創傷治療ドレッシング材 |
JP2022113662A (ja) * | 2021-01-25 | 2022-08-04 | ウルトラ ヴイ カンパニー リミテッド | フィラー用生分解性高分子微粒子、これを含むフィラー用凍結乾燥体、その製造方法及び前記凍結乾燥体を含むフィラー用注射剤 |
JP7312865B2 (ja) | 2021-01-25 | 2023-07-21 | ウルトラ ヴイ カンパニー リミテッド | フィラー用凍結乾燥体の製造方法及び前記凍結乾燥体を含むフィラー用注射剤の製造方法 |
KR102439335B1 (ko) * | 2021-12-10 | 2022-09-02 | 주식회사 엠케이바이오텍 | 태반-유래 줄기세포를 함유하는 피부 재생용 바이오패치형 세포치료제 |
WO2023106513A1 (ko) * | 2021-12-10 | 2023-06-15 | 주식회사 엠케이바이오텍 | 태반-유래 줄기세포를 함유하는 피부 재생용 바이오패치형 세포치료제. |
Also Published As
Publication number | Publication date |
---|---|
KR20170140315A (ko) | 2017-12-20 |
CN107847633A (zh) | 2018-03-27 |
WO2017011050A3 (en) | 2017-04-13 |
AU2016294135A1 (en) | 2017-11-09 |
HK1250220A1 (zh) | 2018-12-07 |
US20180078423A1 (en) | 2018-03-22 |
EP3285783B1 (en) | 2020-09-16 |
WO2017011050A2 (en) | 2017-01-19 |
US11458042B2 (en) | 2022-10-04 |
EP3285783A4 (en) | 2019-01-02 |
CN107847633B (zh) | 2021-06-29 |
CA2983292A1 (en) | 2017-01-19 |
EP3285783A2 (en) | 2018-02-28 |
AU2016294135A8 (en) | 2017-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018512959A (ja) | 治癒向上のための二層デバイス | |
Cao et al. | Recent advances in regenerative biomaterials | |
US9848987B2 (en) | Joint bioscaffolds | |
Tabesh et al. | The role of biodegradable engineered scaffolds seeded with Schwann cells for spinal cord regeneration | |
Gnavi et al. | The use of chitosan-based scaffolds to enhance regeneration in the nervous system | |
DE69534083T2 (de) | Brustgewebetechnologie | |
ES2662331T3 (es) | Matrices tisulares regenerativas | |
US9937278B2 (en) | Biocompatible and biodegradable gradient layer system for regenerative medicine and for tissue support | |
Antmen et al. | The role of biomaterials and scaffolds in immune responses in regenerative medicine: macrophage phenotype modulation by biomaterial properties and scaffold architectures | |
BR112019013403A2 (pt) | Método e matriz produzida por eletrofiação | |
Yang et al. | Emerging 3D bioprinting applications in plastic surgery | |
EP3230044A1 (en) | Graft scaffold for cartilage repair and process for making same | |
CN105283207B (zh) | 使用可降解的聚合物基纳米复合材料的骨再生及其应用 | |
Xia et al. | Emerging polymeric biomaterials and manufacturing techniques in regenerative medicine | |
Jemni-Damer et al. | First steps for the development of silk fibroin-based 3D biohybrid retina for age-related macular degeneration (AMD) | |
RU2533457C1 (ru) | Биоактивный резорбируемый пористых 3d-матрикс для регенеративной медицины и способ его получения | |
EP3773770B1 (en) | Compositions and methods for preparing and using non-immunogenic fast annealing microporous annealed particle hydrogels | |
JP5935181B2 (ja) | 創傷治癒用の生体材料およびその調製 | |
Naghibzadeh | Nanofibers for Skin Regeneration. | |
KR102494197B1 (ko) | 연골 성분 기반 바이오 잉크를 이용한 소이증 치료 목적 구조체 제작용 조성물 및 그 제조방법 | |
Chandy | Nerve tissue engineering on degradable scaffold | |
Kraan et al. | Developing equine liver organoids for nutritional studies and (metabolic) disease modeling | |
Philips et al. | Challenges and pitfalls for determination of DNA content in decellularized skeletal muscle tissue | |
Pacheco et al. | MODELLING THE AIRWAY MUCUS MICROENVIRONMENT TO BE APPLIED ON CYSTIC FIBROSIS THERAPY | |
Mehr | Highly structured and surface modified poly (ε-caprolactone) scaffolds derived from co-continuous polymer blends for bone tissue engineering. ProQuest Dissertations and Theses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171219 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190409 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200123 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200204 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200629 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201006 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201225 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210511 |